Yazanel O.Canoruc F.Isikoglu B.2024-04-242024-04-2419961300-4948https://hdl.handle.net/11468/24155For active immunization against infection caused by hepatitis B virus, 25 hemodialysis patients (13 men, 12 women, 15-62 years old range) were vaccinated with the close of 20-40 microgram recombinant DNA vaccine, three times one month apart. At the first evaluation 2 months after the last vaccination, we were able to include in the study 24 hemodialysis patients and 27 healthy relatives. Of 24 hemodialysis patients, 14 (58.3%) and of 27 healthy relatives, 25 (93%) developed anti-HBs antibody. Six months after the last vaccination (second evaluation), two men more had anti-HBs antibody. Thus, totally 16 hemodialysis patients responded to hepatitis B vaccination (66.6%). Immune reactivity seems to correlate with the uremic (p<0.05) and nutritional status. Women were more likely (75%) to be responder than men (50%), and the younger patients (<40 years old) correlated significantly with the antibody response. In conclusion, since these patients had a poor antibody response to standard vaccination, alternative hepatitis B vaccination regimens may have to be planned in this particular group of patients.trinfo:eu-repo/semantics/closedAccessAnti-Hbs AntibodyChronic Hemodialysis PatientsHepatitis B (Hb) VaccinationArticle721311352-s2.0-0029950161N/A